Extendicare Inc. (TSE:EXE – Get Free Report) shares hit a new 52-week high on Thursday . The company traded as high as C$29.47 and last traded at C$29.47, with a volume of 88760 shares. The stock had previously closed at C$28.81.
Wall Street Analysts Forecast Growth
A number of equities research analysts have weighed in on the stock. National Bank Financial upped their price objective on shares of Extendicare from C$24.50 to C$29.00 and gave the stock an “outperform” rating in a report on Thursday, February 5th. TD Securities upgraded shares of Extendicare from a “hold” rating to a “buy” rating and upped their price objective for the stock from C$19.00 to C$32.00 in a report on Monday. Canadian Imperial Bank of Commerce upped their price objective on shares of Extendicare from C$22.00 to C$32.00 in a report on Thursday, April 2nd. Finally, BMO Capital Markets upped their price objective on shares of Extendicare from C$24.00 to C$30.00 in a report on Monday, March 2nd. One analyst has rated the stock with a Strong Buy rating and four have issued a Buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of C$28.64.
View Our Latest Report on Extendicare
Extendicare Stock Up 3.0%
Extendicare (TSE:EXE – Get Free Report) last issued its earnings results on Thursday, February 26th. The company reported C$0.29 earnings per share (EPS) for the quarter. Extendicare had a net margin of 5.82% and a return on equity of 47.65%. The company had revenue of C$462.03 million for the quarter. On average, analysts predict that Extendicare Inc. will post 0.6134729 EPS for the current year.
Extendicare Company Profile
Extendicare Inc, operating solely in Canada, is the largest private-sector owner and operator of long-term care (LTC”) homes and one of the largest private-sector providers of publicly funded home health care services.
See Also
Receive News & Ratings for Extendicare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Extendicare and related companies with MarketBeat.com's FREE daily email newsletter.
